Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00619645 · OUTCOME

Number of Patients Without Progression After Day 100 Transplant

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers · Source last updated 2018-01-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
24 months after day 100 transplant

What was measured

All patients will be followed for progression for 24 months after their day 100 transplant.

Analysis population: This outcome was not collected/analyzed

Groups in this outcome

RIST for Heme Malignancies

Busulfan 3.3 mg/kg over 3 hours on day -6 and day -5 Fludarabine 30 mg/m2 IV over 30 minutes on day -6 to day -2 followed by Transplant followed by Immunosuppressive/GVHD therapy busulfan cyclosporine fludarabine phosphate mycophenolate mofetil allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
RIST for Heme Malignancies0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
All patients will be followed for progression for 24 months after their day 100 transplant.
groups
  1. description
    Busulfan 3.3 mg/kg over 3 hours on day -6 and day -5 Fludarabine 30 mg/m2 IV over 30 minutes on day -6 to day -2 followed by Transplant followed by Immunosuppressive/GVHD therapy busulfan cyclosporine fludarabine phosphate mycophenolate mofetil allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation
    id
    OG000
    title
    RIST for Heme Malignancies
population Description
This outcome was not collected/analyzed
reporting Status
POSTED
time Frame
24 months after day 100 transplant
title
Number of Patients Without Progression After Day 100 Transplant
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice